
OR WAIT null SECS
Patricia Bloom, MD, discusses treatment gaps in hepatic encephalopathy and the role of adjunctive therapies in 2026 ACG guidance.
Despite lactulose and rifaximin remaining the foundation of hepatic encephalopathy (HE) management, patients may continue to experience cognitive symptoms and recurrent episodes of overt HE. Patricia Bloom, MD, assistant professor and transplant hepatologist in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota, estimates existing therapies address roughly half of the clinical burden, leaving a substantial need for additional treatment options.
In an interview with HCPLive, Bloom discussed why new HE therapies have been slow to reach clinical practice, the limitations of targeting ammonia alone, and how clinicians might approach older adjunctive treatments in patients with persistent symptoms.
Bloom presented “Beyond Lactulose and Rifaximin: Emerging Pharmacological Approaches to Hepatic Encephalopathy and Quality of Life” during a joint session of the American Association for the Study of Liver Diseases (AASLD) and the Indian National Association for Study of the Liver at AASLD The Liver Meeting 2026, held November 5-9 in Denver, Colorado.¹
Lactulose remains a first-line treatment for overt HE, with rifaximin commonly added for recurrent episodes. However, preventing recurrence does not necessarily eliminate the cognitive impairment, functional limitations, and quality-of-life burden associated with HE.
“Lactulose and rifaximin treat about 50% of the overall symptoms of hepatic encephalopathy and prevent about 50% of those severe overt episodes,” Bloom said. “So it’s not that we have nothing. We are treating 50% of those symptoms and episodes, but we still clearly have this huge unmet burden.”
Bloom's estimate reflects her assessment of the remaining treatment gap rather than a single comparative efficacy measure. The clinical challenge extends beyond controlling acute episodes to managing patients who continue to experience symptoms despite established therapy.
Developing additional treatments has proven difficult, in part because of the complexity of the population enrolled in HE trials. Patients frequently have advanced cirrhosis and competing complications, including ascites, variceal bleeding, infections, and the possibility of liver transplantation.
These events can interrupt treatment or follow-up, complicate the interpretation of clinical outcomes, and increase the number of participants needed to demonstrate a treatment effect. Bloom identified these practical barriers, along with the cost of conducting sufficiently large studies, as contributors to the slow pace of HE drug development.
Another challenge is identifying which mechanisms new therapies should target.
Ammonia has long been central to HE pathophysiology and treatment development. However, Bloom emphasized its role is only one component of a more complex disease process involving neuroinflammation and other metabolic disturbances.
Although reducing ammonia remains an important therapeutic strategy, Bloom described the need for treatments addressing additional pathways involved in cognitive dysfunction.
Inflammation represents one potential target, but its broad involvement in cirrhosis and HE makes identifying specific therapeutic mechanisms difficult. Bloom suggested further research into the metabolites and biological pathways contributing to HE may be necessary before more targeted treatments can be developed.
The distinction is clinically relevant because persistent symptoms despite lactulose and rifaximin do not necessarily indicate a need for more aggressive ammonia reduction alone. They also underscore the importance of evaluating precipitating factors, competing causes of cognitive impairment, and other contributors to recurrent HE.
The American College of Gastroenterology's (ACG) first comprehensive HE guideline, published in March 2026, includes 24 recommendations addressing diagnosis, treatment, recurrence prevention, nutrition, and other aspects of care.²
Several older adjunctive therapies have been investigated for HE, including zinc, polyethylene glycol (PEG), branched-chain amino acids (BCAAs), and L-ornithine L-aspartate (LOLA). However, their potential roles differ considerably, and none has displaced lactulose and rifaximin as a mainstay of management.
For patients with overt HE who continue to experience symptoms despite lactulose and rifaximin, the guideline conditionally suggests adding zinc supplementation when blood zinc levels are low. The recommendation is supported by very low-certainty evidence and does not extend to routine supplementation in patients without documented low zinc levels.²
PEG has a different role. The guideline conditionally suggests high-volume PEG preparations as an alternative to lactulose for acute overt HE, based on low-certainty evidence.² This recommendation should be distinguished from long-term prevention of recurrent episodes, for which lactulose remains a central treatment.
Bloom also addressed interest in replacing lactulose with PEG more broadly. Although both agents promote catharsis, she noted lactulose has additional effects on the intestinal microbiome. In her practice, Bloom described reserving PEG for selected patients with constipation and persistent HE rather than routinely substituting it for lactulose.
BCAAs are primarily relevant to nutritional management. The guideline recommends BCAA supplementation when patients cannot meet their protein requirements through dietary intake alone, while emphasizing adequate protein intake rather than protein restriction.²
LOLA, an ammonia-lowering agent, has also been studied in HE, although its clinical use and evidence base differ from those of zinc, PEG, and nutritional supplementation. Its potential role should not be interpreted as equivalent to the guideline-supported indications for the other agents.
Bloom emphasized the limited clinical impact she expects from these older approaches.
“None of those 4 therapies are going to revolutionize hepatic encephalopathy care,” she said. “They are probably working to help some people a little bit at the margins in very specific situations.”
For clinicians, the distinction is between using an adjunctive treatment for a defined indication and expecting it to address the broader burden of persistent HE. The 2026 guideline provides additional options for selected patients, but the need for therapies capable of producing more substantial and sustained improvements remains.
Editor's Note: Bloom reports relevant disclosures with Nexilico and Vedanta Biosciences.